Paclitaxel and Carboplatin Combination Chemotherapy in a Hemodialysis Patient with Advanced Ovarian Cancer

Watanabe, Minoru; Aoki, Yoichi; Tomita, Masatoshi; Sato, Takaaki; Takaki, Y.; Kato, Nozomi; Kikuchi, Masatoshi; Kase, Hiroaki; Tanaka, Kenichi

doi:10.1006/gyno.2001.6527

Cited by 39 publications

(41 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, similar to many previous investigations [4][5][6][7][8], patients requiring hemodialysis received carboplatin at an AUC-based dosage, with the GFR assumed to be 0, and hemodialysis was then started 23 h after the end of carboplatin infusion. An important advantage of this strategy is that extensive data on AUC-based carboplatin chemotherapy obtained from patients with normal renal function can be applied.…”

Section: Discussionmentioning

confidence: 94%

“…To our knowledge, only a few case reports or very small studies have documented patients with severe renal insufficiency who received carboplatin for the treatment of cancer [4][5][6][7][8][9][10][11]. In this present study, we investigated the practical application of the Calvert formula in adult patients with severe renal insufficiency in whom GFR was exactly measured by inulin clearance or who were receiving maintenance hemodialysis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Extension of the Calvert formula to patients with severe renal insufficiency

Oguri

Shimokata

Ito

et al. 2015

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Extension of the Calvert formula to patients with severe renal insufficiency

Oguri

Shimokata

Ito

et al. 2015

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…In a case in which 125 mg of carboplatin was administered to produce a target AUC of 5.0 mg/ml min, the actual AUCs were reported at 2.21, 4.43, and 6.1 mg/ml min when hemodialysis was started after 1.5-, 16-, and 24-h administration of carboplatin, respectively [18,19]. Grade 3 neutropenia was observed when conditions for the start of hemodialysis were modified at 16-h (but not at 1.5-h) after carboplatin administration [19]. For the current case, hemodialysis was started 1-h after carboplatin administration in the distribution phase due to safety concerns.…”

Section: Discussionmentioning

confidence: 99%

Carboplatin and weekly paclitaxel chemotherapy in hemodialysis patient with advanced lung cancer and severe comorbidity: effect of the drugs and their chemical intermediates

Tanaka

2014

Res Chem Intermed

View full text Add to dashboard Cite

In advanced non-small-cell lung cancer (NSCLC) patients with severe comorbidity or who are elderly, significant differences exist at the induction of chemotherapy. A 68-year-old man with a history of severe aortic stenosis and cerebral infarction had been receiving hemodialysis for end-stage renal disease. On admission due to loss of consciousness caused by aortic stenosis, a mass in the upper lobe of the right lung with a small amount of pleural effusion was detected. The patient was diagnosed with adenocarcinoma of lung (cT2bN1M1a, stage IV). A weekly regimen of paclitaxel in combination with carboplatin is less toxic than the standard regimen of administering both simultaneously. Therefore, this regimen is preferable for patients with severe comorbidity or who are elderly. For the present case, combination chemotherapy of carboplatin and weekly paclitaxel was selected and administered for four cycles. Tumor response was evaluated as stable disease and adverse events were tolerable. This combination was found to be a candidate regimen for advanced NSCLC patients receiving hemodialysis with severe comorbidity.

show abstract

“…Therefore, the plasma concentration of carboplatin is affected by the dose and timing of treatment in addition to the duration of hemodialysis. Several studies have reported the use of carboplatin-based therapy during hemodialysis (Table) (8)(9)(10)(11). However, as of yet, there is no established consensus regarding the optimal timing and duration of hemodialysis with respect to the chemotherapy regimen in hemodialysis patients.…”

Section: Discussionmentioning

confidence: 99%

Advanced Thymic Cancer Treated with Carboplatin and Paclitaxel in a Patient Undergoing Hemodialysis

et al. 2015

View full text Add to dashboard Cite

A 53-year-old man with an asymptomatic anterior mediastinal tumor undergoing hemodialysis was referred to our institution. He was diagnosed with thymic basaloid carcinoma based on the findings of a chest tomography-guided biopsy and successfully treated with carboplatin (300 mg/m 2 /day) and paclitaxel (200 mg/ m 2 /day) on day 1 for six three-week cycles. To our knowledge, this is the first report regarding the efficiency of a carboplatin dose-definition method based on the body surface area with paclitaxel in a hemodialysis patient. This report may therefore be useful for treating hemodialysis patients who are candidates for carboplatin and paclitaxel therapy.

show abstract

Paclitaxel and Carboplatin Combination Chemotherapy in a Hemodialysis Patient with Advanced Ovarian Cancer

Cited by 39 publications

References 8 publications

Extension of the Calvert formula to patients with severe renal insufficiency

Extension of the Calvert formula to patients with severe renal insufficiency

Carboplatin and weekly paclitaxel chemotherapy in hemodialysis patient with advanced lung cancer and severe comorbidity: effect of the drugs and their chemical intermediates

Advanced Thymic Cancer Treated with Carboplatin and Paclitaxel in a Patient Undergoing Hemodialysis

Contact Info

Product

Resources

About